Non-pharmacological therapies for postviral syndromes, including Long COVID: a systematic review and meta-analysis protocol

Joht Singh Chandan, Kirsty Brown, Nikita Simms-Williams, Jenny Cameradou, Nasir Bashir, Dominic Heining, Olalekan Lee Aiyegbusi, Grace Turner, Samantha Cruz Rivera, Richard Hotham, Krishnarajah Nirantharakumar, Manoj Sivan, Kamlesh Khunti, Devan Raindi, Steven Marwaha, Sarah E Hughes, Christel McMullan, Melanie Calvert, Shamil Haroon.

ABSTRACT

Introduction

Postviral syndromes (PVS) describe the sustained presence of symptoms following an acute viral infection, for months or even years. Exposure to the SARS-CoV-2 virus and subsequent development of COVID-19 has shown to have similar effects with individuals continuing to exhibit symptoms for greater than 12 weeks. The sustained presence of symptoms is variably referred to as ‘post COVID-19 syndrome’, ‘post-COVID condition’ or more commonly ‘Long COVID’. Knowledge of the long-term health impacts and treatments for Long COVID are evolving. To minimise overlap with existing work in the field exploring treatments of Long COVID, we have only chosen to focus on non-pharmacological treatments.

Aims

This review aims to summarise the effectiveness of non-pharmacological treatments for PVS, including Long COVID. A secondary aim is to summarise the symptoms and health impacts associated with PVS in individuals recruited to treatment studies.

Methods and analysis

Primary electronic searches will be performed in bibliographic databases including: Embase, MEDLINE, PsycINFO, CINAHL and MedRxiv from 1 January 2001 to 29 October 2021. At least two independent reviewers will screen each study for inclusion and data will be extracted from all eligible studies onto a data extraction form. The quality of all included studies will be assessed using Cochrane risk of bias tools and the Newcastle-Ottawa grading system. Non-pharmacological treatments for PVS and Long COVID will be narratively summarised and effect estimates will be pooled using random effects meta-analysis where there is sufficient methodological homogeneity. The symptoms and health impacts reported in the included studies on non-pharmacological interventions will be extracted and narratively reported.

Ethics and dissemination

This systematic review does not require ethical approval. The findings from this study will be submitted for peer-reviewed publication, shared at conference presentations and disseminated to both clinical and patient groups.

Strengths and limitations of this study

► This review will provide the first comprehensive and systematic summary of non-pharmacological treatments for postviral syndromes.
► The review proposal has been strengthened through its codevelopment with individuals with lived experience of Long COVID.
► A limitation of the review relates to the heterogeneity in the definition of post-viral syndromes as well as Long COVID, adding complexity to the synthesis of available evidence across the included syndromes.
► There is likely to be significant methodological heterogeneity in clinical trials of non-pharmacological interventions for postviral syndromes, which may limit our ability to pool treatment effects.

Prospero registration number

The review will adhere to this protocol which has also been registered with Prospero (CRD42021282074).

BACKGROUND

Globally, there have been over 480 million cases of COVID-19 with over 6 million associated deaths. The pandemic has triggered a concerted global effort to develop and deliver safe and efficacious vaccinations at record speed, which have now significantly reduced morbidity, mortality and disease transmission associated with SARS-CoV-2.

Despite such positivity, the long-term sequelae of even mild infections of COVID-19 appear to carry a substantive burden on some patients, their families and health services. Early evidence suggested that the average recovery time following an acute COVID-19 infection is 2–3 weeks, depending...
on symptom severity. However, as the pandemic has progressed it became apparent that not all patients immediately recovered from the initial infection and between 2.3% and 37% develop symptoms lasting greater than 12 weeks, some of which may be relapsing and remitting. However, prevalence estimates in these longer-term symptoms vary because of differences in disease definition (including differences in symptom severity and included symptoms), population surveyed and study design.

There is considerable heterogeneity in the clinical definition of ongoing symptoms following initial exposure to SARS CoV-2. The National Institute for Health and Care Excellence define symptoms persisting beyond 4 weeks as either ‘ongoing symptomatic COVID-19’ (symptoms lasting between 4 and 12 weeks) or ‘Post COVID-19 syndrome’ (symptoms lasting beyond 12 weeks). Globally other terms such as ‘post-COVID condition’ or ‘long haulers’ are used. However, in the UK, the more commonly adopted and preferred term among healthcare professionals and patient groups for ongoing symptoms following initial viral exposure to SARS CoV-2 is ‘Long COVID’, the term adopted for this review.

The prevalence of persistent signs and symptoms, the remitting, relapsing and interchangeable nature of these symptoms, the pathophysiology and clinical course of Long COVID, and the lived experiences of patients, is yet to be fully described. However, many clinical sequelae including, but not limited to, fatigue, respiratory, neurological, psychological and gastroenterological complications that present in patients with Long COVID also feature in a similar pattern following other acute viral infections.

An improved understanding of the sequelae and particularly the management of existing post-viral syndromes secondary to acute infections may provide further insight and guidance as to the optimal management of patients with Long COVID. Despite the novelty of the condition, it is clear that optimal management involves a multidisciplinary approach and rehabilitation, with patient involvement being a central component.

Postviral syndromes may occur secondary to exposure to a number of acute viral infections, including but not limited to Coronavirusidae, Filoviridae, Herpesviridae, Orthomyxoviridae, Picornaviridae, Parvoviridae, Togaviridae and Flaviviridae, as defined by the International Committee on Taxonomy of Viruses. Like Long COVID, the signs and symptoms comprising these post-viral syndromes may include fatigue, musculoskeletal pain (eg, joint pain) and mood (eg, feeling depressed) and neurocognitive disturbances (eg, difficulties with concentration and sleep). Particularly researched area has been the development of postinfectious fatigue following Epstein-Barr virus (EBV) exposure. As we have demonstrated in our recently published review on the symptoms of Long COVID, fatigue is one of the most commonly reported symptoms. Notably, over time interventions have been developed to support patients with Epstein-Barr postinfectious fatigue, such as the combination of cognitive–behavioural therapy with music therapy which has shown some promise. This example highlights the similarities that may exist between postviral syndromes and the need to summarise evidence on their treatments, which may be relevant to those experiencing Long COVID.

Although the pathophysiology of postviral syndromes is poorly understood, it has been hypothesised that their development is mediated by altered cytokine responses, neuroinflammation, mitochondrial dysfunction and microbiome dysbiosis. A culmination of the pathophysiological changes and phenotypes following acute viral infections, including COVID-19, have been likened to other poorly understood conditions such as myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Despite the limited evidence and clinical consensus, guidelines for the management of Long COVID have been developed and trials are underway exploring the impact of pharmaceutical, dietary and lifestyle interventions.

Considering the significant individual and societal burden arising from the COVID-19 pandemic there is an urgent need to identify whether the existing knowledge base on similar postviral syndromes can be applied to support the clinical management of patients with Long COVID. A comprehensive synthesis of the evidence on postviral syndromes, including on their therapies, is needed to better support those with Long COVID as well as those with previous post-viral syndromes. To minimise overlap with existing work in the field exploring pharmacological treatments for Long COVID and on the basis of the advice of our expert advisory group, we have chosen to focus on non-pharmacological treatments.

OBJECTIVES

This systematic review will summarise the evidence on non-pharmacological treatments for post-viral syndromes, including Long COVID. The findings will be used to make recommendations on non-pharmacological treatments for Long COVID as well as previous postviral syndromes.

This systematic review will be conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and this protocol has been written in accordance with the PRISMA-Protocols checklist (online supplemental file 1).

METHODS

Eligibility criteria

We will include primary research studies. For non-pharmacological treatments effects, we will consider randomised and non-randomised controlled trial evidence evaluating interventions for patients with post-viral syndromes and will additionally include observational studies (cohort, case cross-over and case–control study designs) for studies focusing on Long COVID.
There will be no restrictions on setting (ie, community or hospital based). Studies published in the previous 20 years will be included (study period defined as from 1 January 2001 to 29 October 2021), as this would encompass research on the first SARS and MERS outbreak which are the two pandemic viruses most related to SARS-CoV-2. No language restrictions will be applied. Peer-reviewed published studies, preprint articles and other grey literature will also be included in this review.

We will include studies with a population consisting of adults and/or children with postviral syndromes. Studies investigating postviral syndromes following acute infections from the following families (grouped by the International Committee on Taxonomy of Viruses)18 will be included in this review.

Viruses known to cause symptomatic acute viral infections will be included. This is based on an assessment of clinically relevant viruses extracted from ‘Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, ninth Edition’.41 Included in brackets are the relevant clinical infections used to inform search terms:

Coronaviridae (Middle East Respiratory Syndrome-Coronavirus, Severe Acute Respiratory Syndrome-Coronavirus, and other coronaviruses), Filoviridae (Ebola, Marburg), Herpesviridae (Epstein-Barr Virus, Cytomegalovirus, Varicella Zoster Virus, Other Human Herpes Viruses, Herpes Simplex Virus), Orthomyxoviridae (Influenza, A, B, C and D), Picornaviridae (Coxackie, Hepatitis A, Enterovirus including Rhinovirus), Paroviridae (Parovirus), Togaviridae (Ross River virus, Chikungunya, other Semliki Forest Complex Viruses), Flaviviridae (West Nile River Virus, Dengue, Yellow Fever, Zika), Reoviridae (Rotavirus), Paramyxoviridae (Mumps, Measles, Parainfluenza, Respiratory Syncytial Virus, Human Metapneumovirus) Adenoviridae (Adenoviruses), Caliciviridae (Norovirus, Sapovirus), Astroviridae (Astroviruses). Additionally, when examining treatment options for Long COVID we will also include studies relating to SARS-CoV-2.

Extremely rare viral infections will not be included, as there is unlikely to be published research relevant to this review. Predominantly asymptomatic viruses, viruses identified in the last 3 years (except for SARS-CoV-2), and viruses predominantly existing as zoonoses will all be excluded, in addition to studies on chronic viral infections including Hepatitis B, Hepatitis C and HIV postviral syndromes. Studies which include demonstrable reactivation of latent infection (eg, EBV, CMV with detectable viral load) will be excluded. We will exclude in vitro and animal studies. Studies that principally focus on ME and CFS without reference to pre-specified viruses will also be excluded.

To the authors’ knowledge, there is no internationally agreed definition of post-viral syndromes and as such there is likely to be heterogeneity in the temporal description of syndrome onset following the initial viral exposure. Where temporal criteria are included, we will aim to include those with symptoms lasting beyond 12 weeks (in line with the minimum timeframe for Long COVID used by the WHO).42 However we will also include publications which provide no firm timeframe but indicate an aspect of chronicity or symptoms persisting for a prolonged period. Additionally, like Long COVID, patients with post-viral syndromes can experience a wide range of symptoms ranging from respiratory complications to fatigue or musculoskeletal pain.

The outcomes of the study will be changes in symptoms, exercise capacity, quality of life (including changes in mental health and well-being) and work capability. Although these are numerous and heterogeneous in nature, some examples of non-pharmacological treatments which may be used to support patients include pacing, cognitive behavioural therapy and pulmonary rehabilitation. Additionally, where described in the included studies, we will also extract information on the symptoms and health impacts reported by participants in the included studies.

In summary, the population will consist of either people with a post-viral syndrome who contributed to a randomised controlled trial or those with Long COVID who either contributed to an observational study or a randomised controlled trial. We will include studies that have assessed the effectiveness of non-pharmacological interventions designed to improve symptoms of postviral syndromes against standard care, an alternative non-pharmacological therapy, or a placebo. The outcomes will be changes in symptoms, exercise capacity, quality of life (including changes in mental health and well-being), and work capability.

Information sources
Primary electronic searches will be performed in Embase, MEDLINE, PsycINFO, CINAHL, COVID-NMA and preprint servers (MedRxiv up to the first 500 references) from 1 January 2001 to 29 October 2021. The reference lists of all eligible articles will also be searched to identify any additional eligible studies which were not identified during the original search. Secondary searches will be conducted for grey literature on databases such as Google Scholar (limited to the first 500 references). Abstracts, conference and symposia proceedings from relevant organisations relating to virology will be identified and examined.

Search methods for identification of studies
The search strategy broadly includes terms such as: “MERS-COV”, “SARS-COV”, “Coronavirus”, “Ebola”, “Epstein-Barr Virus”, “EBV”, “Cytomegalovirus”, “CMV”, “Herpes”, “Influenza”, “Swine flu”, “Coxsackie”, “Parovirus”, “Ross River virus”, “Chikungunya”, “West Nile River virus”, “Long COVID”, “Post-acute COVID”, “Dengue”, “treatment”, “management”, “Post-viral”, “Quality of life”, “Outcomes”. A more extensive list of search terms is attached in online supplemental file 2.
Studies will not be excluded on language. Where studies are not published in English then they will be translated using Google Translate or a by a member of staff at the Institute of Applied Health Research.

**Study records**

**Data management, selection and data collection processes**
The study selection procedure will consist of four steps documented using a PRISMA flow diagram with reviewer decisions recorded at each stage:

1. The search results will be downloaded onto an excel file which will be imported onto the online review software COVidence where the results will be deduplicated. Titles with abstracts will be initially screened by at least two reviewers using predefined screening criteria based on whether studies (1) included patients with a diagnosis of a post-viral syndrome and (2) included information about non-pharmacological treatments.

2. Following title and abstract screening by two reviewers, any disagreements will be resolved through discussion. Where disagreements remain following discussion, these will be reconciled involving an additional reviewer.

3. Full texts of the selected articles will be obtained, and exclusion criteria applied by at least two independent reviewers.

4. As in step 2, selection of included articles will be discussed until a consensus is reached between the reviewers, with an additional reviewer providing support to resolve disagreements. The conclusion of step 3 will provide the final list of studies eligible for inclusion in the review.

The data from all eligible studies will be extracted onto an extraction form by at least one reviewer, with a quarter of extracted studies checked by a second reviewer. In the event where the full text is not available, we will contact the study’s corresponding author for access either via their email address provided for the article or ResearchGate.

**Data items**

Data will be extracted for all eligible studies including first author, year of publication, study design, study setting (community or hospital), country, participant characteristics (age, sex, ethnicity), name of virus and outcome measures. A draft of the data extraction tables can be seen in online supplemental file 3.

**Outcomes and prioritisation**

Data will be sought for the type of non-pharmacological treatment/intervention. The outcomes will be changes in symptoms, exercise capacity, quality of life (including changes in mental health and well-being) and work capacity. Data on the symptoms, health impacts and complications experienced by patients at study entry included in the studies will also be extracted where available.

**Risk of bias in individual studies**

To assess the risk of bias in individual studies we will use the appropriate tool for each type of study. Cochrane risk of bias tools will be used for randomised (ROB 2) and non-randomised (ROBINS-I) controlled trials, and the Newcastle Ottawa tool will be used for observational studies. The risk of bias will be examined by two reviewers and reported using the respective tools.

**Data synthesis**

The review findings will present the non-pharmacological treatments for previous postviral syndromes and Long COVID.

The review will consist of a narrative and quantitative synthesis of included studies if appropriate. The characteristics (study design, population, setting, viruses, etc) and findings of included studies will first be narratively described and summarised in tables. The outcomes (treatment effects (mean differences or measures of relative risk)) will be presented on forest plots to assess the heterogeneity of study findings. The methodological heterogeneity of studies will be qualitatively evaluated and then assessed using the $I^2$ statistic. We will assess clinical heterogeneity by examining the types of participants, interventions and outcomes in each study. We anticipate considerable heterogeneity, particularly in exposure definition (post-viral syndromes or Long COVID), due to differing temporal definitions, viral types and nature of symptoms, and thus where meta-analysis is considered appropriate will undertake a random effects meta-analysis rather than a fixed effect model.

Where outcomes are measured using a continuous scale, these will be pooled through calculation of the weighted mean difference (with SD). Where outcomes are assessed using different continuous measures across the studies, these will be pooled using Hedges’ $g$ standardised mean difference. Where outcomes are assessed using a dichotomous measure, these will be pooled through calculation of ORs.

In line with Cochrane guidance for systematic reviews on dealing with missing data, when appropriate we will not impute missing data but will omit the data from the respective analysis being conducted.

**Additional analyses**

Where there is sufficient data, we will conduct a subgroup analysis comparing hospitalised to non-hospitalised patients and observing any differences in outcomes. We will also where possible undertake a meta-regression model to assess the impact of age and sex on symptoms and treatment effects. Additionally, as a sensitivity analysis we will repeat the primary analysis using high quality studies only.

If at least 10 studies are included in the meta-analysis with no significant evidence of heterogeneity a funnel plot will be used to explore the existence of publication bias by visual inspection. We will also undertake an objective assessment of publication bias using Egger’s regression test. Asymmetry of the funnel plot and/or statistical significance of Egger’s regression test ($p<0.05$) will be indicative of publication bias.
Confidence in cumulative evidence

At least two independent reviewers will assess the strength of the body of evidence (according to the following categories: high, moderate, low and very low) for each individual outcome using the five Grades of Recommendations, Assessment, Development and Evaluation (GRADE) considerations for downgrading the certainty of evidence (risk of bias, imprecision, inconsistency, indirectness and publication bias) and the three GRADE considerations for upgrading the certainty of evidence (large magnitude of effect, dose-response gradient and residual confounding decreasing the overall effect).49

Patient and public involvement

Patients and the public were involved in the development of the research question and design of the review. This was undertaken with the support of a working patient and public involvement and engagement (PPIE) group. We held an initial meeting with members of the PPIE group. Members of the research team gave a presentation which highlighted the similarity between postviral syndromes and Long COVID, the rationale for this review as well as our preliminary ideas. There were four PPIE group members in attendance—two white men and two women (one black and the other South-East Asian). Following the presentation, there was a discussion of the review objectives. The PPIE group members were asked for their thoughts on the review objectives and its scope. While they confirmed that the objectives were appropriate and comprehensive, they stressed the impact of Long COVID on employment and that the loss of income was very important to patients. Therefore, a key goal of this work should be to identify potential non-pharmacological interventions that will facilitate the rehabilitation of patients with long COVID so that they can be fit to return to work. Based on their feedback, we will ensure that this review will report interventions designed to improve the physical function of patients which will facilitate their return to work. Patients and members of the public will not be involved in the study selection or extraction phases but will be involved with the evidence synthesis stage. At this subsequent stage their involvement will be documented according to the GRIPP-2 checklist.50 The final review, and a lay summary will be disseminated via publication and conference presentations which will be supported with the PPIE group.

ETHICS AND DISSEMINATION

As the primary focus of the review will be to undertake a secondary analysis of published data, no ethical approval is formally required. The findings from the review will be submitted for peer-reviewed publication, shared at conference presentations, and disseminated to both clinical and patient groups.

Author affiliations

1Institute of Applied Health Research, University of Birmingham, Birmingham, UK

2Health Data Research UK, Birmingham, UK

3COVID END Evidence Network, UK, UK

4School of Dentistry, University of Birmingham, Birmingham, UK

5University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

6Centre for Patient-Reported Outcomes Research, University of Birmingham, Birmingham, UK

7NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

8Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK

9National Institute for Health Research (NIHR) Applied Research Centre West Midlands, University of Birmingham, Birmingham, UK

10University of Leeds, Leeds, UK

11Department of Health Sciences, University of Leicester, Leicester, UK

12Institute for Mental Health, University of Birmingham, Birmingham, UK

13Centre for Patient Reported Outcomes Research and Institute of Applied Health Research, University of Birmingham, Birmingham, UK

Contributors

The research questions were conceived by JSC, KN, MC and SH. The first draft of the protocol was done by KB, NS-W, JSC and SH. Further reviews and revisions to the protocol were made by all remaining co-authors (CM, JC, NB, BH, OLA, GT, KN, MS, KK, DR, SCR, RH, SM, SEH). The final copy of the manuscript was approved by all authors.

Funding

This work is independent research jointly funded by the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) (Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunity to targeted therapies (The TLC Study), COV-LT-0013).

Disclaimer

The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
with viral infection of the myocardial tissue: a meta-analysis of cohort studies. 

23 Schulz JC, Hilliard AA, Cooper LT, et al. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 2009;84:1001–9. doi:10.4065/S0025619611060670-8

24 Chan KS, Zheng JP, Mok YW, et al. Sars: prognosis, outcome and sequelae. Respiratory 2003;8 Suppl:S36–40. doi:10.1046/j.1440-1843.2003.00522.x

25 Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7:611–27. doi:10.1016/S2215-3660(20)30203-0

26 Lee SH, Shin H-S, Park HY, et al. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle East respiratory syndrome survivors. Psychiatry Investig 2019;16:59–64. doi:10.30773/pi.2018.10.22.3

27 Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006;333:575–8. doi:10.1136/bmj.38933.s58764.AE

28 White PD. What causes prolonged fatigue after infectious mononucleosis: and does it tell us anything about chronic fatigue syndrome? J Infect Dis 2007;196:1515–21. doi:10.1086/516155

29 Ayebiwasu OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med 2021;114:428–42. doi:10.1177/01410768211032850

30 Malik S, Asprusten TT, Pedersen M, et al. Cognitive–behavioural therapy combined with music therapy for chronic fatigue following Epstein–Barr virus infection in adolescents: a randomised controlled trial. BMJ Paediatr Open 2020;4:e000797. doi:10.1136/bmjpo-2020-000797

31 Bansal AS, Bradley AS, Bishop KN, et al. Chronic fatigue syndrome, the immune system and virus infection. Brain Behav Immun 2012;26:24–31. doi:10.1016/j.bbi.2011.10.016

32 Proal A, Marshall T. Myalgic Encephalomyelitis/Chronic fatigue syndrome in the era of the human microbiome: persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front Pediatr 2018;6:373. doi:10.3389/fped.2018.00373

33 Yamato M, Katoaka Y. Fatigue sensation following peripheral viral infection is triggered by neuroinflammation: will who answer these questions? Neural Regen Res 2015;10:203–4. doi:10.4103/1673-5374.152369

34 Islam MF, Cotlier J, Jason LA. Post-Viral fatigue and COVID-19: lessons from past epidemics. Fatigue: Biomedicine, Health Behav 2020;8:61–9. doi:10.1016/j.fatigue.2020.05.004

35 Vernon SD, Whistler T, Cameron B, et al. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis 2006;6:15. doi:10.1186/1471-2334-6-15

36 Holgate ST, Komaroff AL, Mangan D, et al. Chronic fatigue syndrome: understanding a complex illness. Nat Rev Neurosci 2011;12:539–44. doi:10.1038/nrn3287

37 Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. BMJ 2021;374:n1684. doi:10.1136/bmj.n1684

38 UKRI. Outcomes of the UK COVID-19 therapeutics Advisory panel (UK-CTAP), 2021. Available: https://www.ukri.org/about-us/policies-standards-and-data-data-collection/uk-covid-19-therapeutics-advisory-panel/ [Accessed 27 Sep 2021]

39 Page MJ, McKenzie JE, Bossuyt PM. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:101.
doi:10.1136/bmj.n1648

40 Bennett JE, Doolin R, Blaser MJ. Principles and practice of infectious diseases, 2019.

41 World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-Clinical_case-definition-2021.1 [Accessed 2 Mar 2022]

42 Veritas health innovation. Covidence systematic review software.

43 Sheu BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that includes both randomised and non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. doi:10.1136/bmj.j4008
Wells G, Shea B, O'Connell D. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hosp Res Inst 2015:2–4.

Sterne JAC, Savović J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:i4898. doi:10.1136/bmj.i4898

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355:i4919. doi:10.1136/bmj.i4919

Cochrane. 16.1.2 general principles for dealing with missing data. Available: https://handbook-5-1.cochrane.org/chapter_16/16_1_2_general_principles_for_dealing_with_missing_data.htm [Accessed 10 Sep 2021].

Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6. doi:10.1136/bmj.39489.470347.AD

Staniszewska S, Brett J, Simera I. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ* 2017;358:j3453.
**Supplementary 1: PRISMA-P checklist**

**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) checklist: recommended items to address in a systematic review protocol**

| Section and topic | Item No | Checklist item                                                                 | Location in manuscript (page number) |
|-------------------|---------|--------------------------------------------------------------------------------|--------------------------------------|
| **ADMINISTRATIVE INFORMATION**                             |         |                                                                                |                                      |
| Title:            | 1a      | Identify the report as a protocol of a systematic review                        | 1                                    |
| Identification    | 1b      | If the protocol is for an update of a previous systematic review, identify as such | N/A                                  |
| Registration      | 2       | If registered, provide the name of the registry (such as PROSPERO) and registration number | 6                                    |
| Authors:          | 3a      | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1                                    |
| Contact           | 3b      | Describe contributions of protocol authors and identify the guarantor of the review |                                      |
| Amendments        | 4       | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | N/A                                  |

Support:
| Sources | 5a | Indicate sources of financial or other support for the review | 1 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | 1 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | 1 |

### INTRODUCTION

| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 5 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 6 |

### METHODS

| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 7 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 8 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 8 and supplementary table 2 |
| Study records: Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 9 |
| Selection process | 1b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 9 |
|-------------------|----|-----------------------------------------------------------------------------------------------------------------|----|
| Data collection process | 1c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 9 and supplementary table 3 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 9 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 9 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | 10 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$, Kendall’s $t$) | 10 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | 10 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) |
|-------------|----|-------------------------------------------------------------------------------------------------------------------|
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) |

*It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.*
Supplementary 2: Draft search terms

Search terms

Virus terms
- Middle eastern respiratory syndrome
  - MERS
- Severe acute respiratory syndrome
  - SARS
- Coronavirus
- Ebola
- Marburg
- Epstein Barr virus
- Cytomegalovirus
- Varicella Zoster Virus
- Other Human Herpes Viruses
- Herpes Simplex Virus
- Influenza
- Influenza A
- Influenza B
- Influenza C
- Influenza D
- Coxsackie
- Hepatitis A
- Enterovirus
- Rhinovirus
- Parvovirus
- Ross River Virus
- Chikungunya
- Semliki Forest Complex Viruses
- West Nile River virus
- Dengue
- Yellow Fever
- Zika
- Rotavirus
- Mumps
- Measles
- Parainfluenza
- Respiratory Syncytial Virus
- Human Metapneumovirus
- Adenoviruses
- Norovirus
• Sapovirus
• Astrovirus*
• COVID

Long-term phrases
• Long-term
• Long-term
• Persistent
• Recurrent
• Chronic
• Post-viral
• Post-infectious
• Post infectious

Treatment terms
• Treatment*
• Therap*
• Intervention
### Supplementary 3: Draft data extraction table

| Author (year) | Setting | Participant characteristics | Name of virus | Outcomes | Intervention | Comparator | Main findings |
|---------------|---------|-----------------------------|---------------|----------|-------------|-----------|--------------|
| N             | Mean age, n (SD) | S Ethnicity (%) |              |          |             |           |              |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).